Lactose Engineering for Better Performance in Dry Powder Inhalers

被引:55
作者
Rahimpour, Yahya [1 ,2 ]
Hamishehkar, Hamed [3 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Drug Appl Res Ctr, Pharmaceut Technol Lab, Tabriz, Iran
关键词
Carrier; Dry powder inhaler; Pulmonary drug delivery; Lactose;
D O I
10.5681/apb.2012.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dry powder inhaler (DPI) is generally formulated as a powder mixture of coarse carrier particles and micronized drug with aerodynamic diameters of 1-5 mu m. Carrier particles are used to improve drug particle flowability, thus improving dosing accuracy, minimizing the dose variability compared with drug alone and making them easier to handle during manufacturing operations. Lactose is the most common and frequently used carrier in DPIs formulations and nowadays various inhalation grades of lactose with different physico-chemical properties are available on the market. Therefore, the purpose of this manuscript is to review evolution of lactose as a carrier in inhalable formulations, their production and the impact of its physico-chemical properties on drug dispersion. This review offers a perspective on the current reported studies to modify lactose for better performance in DPIs.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 44 条
[1]   Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote [J].
Ali, Raisuddin ;
Jain, Gaurav K. ;
Iqbal, Zeenat ;
Talegaonkar, Sushma ;
Pandit, Pragati ;
Sule, Sunita ;
Malhotra, Geena ;
Khar, Roop K. ;
Bhatnagar, Aseem ;
Ahmad, Farhan J. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2009, 5 (01) :55-63
[2]  
Atkins Paul J, 2005, Respir Care, V50, P1304
[3]   Rational design of stable lyophilized protein formulations: Some practical advice [J].
Carpenter, JF ;
Pikal, MJ ;
Chang, BS ;
Randolph, TW .
PHARMACEUTICAL RESEARCH, 1997, 14 (08) :969-975
[4]   Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations [J].
Chan, LW ;
Lim, LT ;
Heng, PWS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) :975-984
[5]   Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development [J].
Crowder, TM ;
Rosati, JA ;
Schroeter, JD ;
Hickey, AJ ;
Martonen, TB .
PHARMACEUTICAL RESEARCH, 2002, 19 (03) :239-245
[6]   Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology [J].
Emami, Jaber ;
Hamishehkar, Hamed ;
Najafabadi, Abdolhossien Rouholamini ;
Gilani, Kambiz ;
Minaiyan, Mohsen ;
Mahdavi, Hamid ;
Mirzadeh, Hamid ;
Fakhari, Amir ;
Nokhodchi, Ali .
JOURNAL OF MICROENCAPSULATION, 2009, 26 (01) :1-8
[7]   Pulmonary delivery of opioids as pain therapeutics [J].
Farr, Stephen J. ;
Otulana, Babatunde A. .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (9-10) :1076-1088
[8]  
Fleischer W., 2005, OPIOIDS TREATMENT CH
[9]   Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety [J].
Geller, David E. ;
Konstan, Michael W. ;
Smith, Jeffrey ;
Noonberg, Sarah B. ;
Conrad, Carol .
PEDIATRIC PULMONOLOGY, 2007, 42 (04) :307-313
[10]   Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules [J].
Hamishehkar, Hamed ;
Emami, Jaber ;
Najafabadi, Abdolhossien Rouholamini ;
Gilani, Kambiz ;
Minaiyan, Mohsen ;
Mandavi, Hamid ;
Nokhodchi, Ali .
POWDER TECHNOLOGY, 2010, 201 (03) :289-295